NASDAQ:PROF
Profound Medical Corp.
Profound Medical Corp.'s revenue grew 50.7% in fiscal 2025 to $16.1M while operating margin rose to −256.3%, its highest in 3 years. Free cash flow was −$38.4M, −238.4% of revenue, and the diluted share count rose 22.1%.Summary generated from Profound Medical Corp.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$16.1M
Revenue growth+50.7%
Revenue, 5-yr CAGRn/a
Gross margin70.8%
Operating margin−256.3%
Net margin−264.4%
ROIC−304.9%
Return on equity−67.1%
Debt / equity0.07
Free cash flow−$38.4M
FCF margin−238.4%
Share count change+22.1%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 7 | 11 | 16 |
| Operating income | −29 | −33 | −41 |
| Net income | −28 | −28 | −43 |
| Free cash flow | n/a | n/a | −38 |
Recent filings
- 8-KRegulation FD disclosure
Oct 9, 2026 - 8-KResults of operations and financial condition
Oct 7, 2026 - 8-KRegulation FD disclosure
Sep 4, 2026 - 8-KDirector or officer change
Sep 3, 2026 - 8-KRegulation FD disclosure
Aug 17, 2026 - 8-KDirector or officer change
Aug 17, 2026 - 8-KRegulation FD disclosure
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026